A Multi-center , Opened, Phase II Study of Safety and Efficacy of Sulfatinib in Advanced Medullary Thyroid Carcinoma ( MTC) and Iodine-refractory Differentiated Thyroid Carcinoma (DTC)
Latest Information Update: 24 Nov 2021
Price :
$35 *
At a glance
- Drugs Surufatinib (Primary)
- Indications Thyroid cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors Hutchison MediPharma
- 18 Nov 2019 Status changed from recruiting to completed.
- 08 Nov 2018 Planned End Date changed from 1 Dec 2018 to 1 Jul 2019.
- 08 Nov 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Jul 2019.